Bitter Melon as a Therapy for Diabetes, Inflammation, and Cancer: a Panacea?

Organization WH. WHO traditional medicine strategy 2002–2005. 2002. Patwardhan B et al. Ayurveda and traditional Chinese medicine: a comparative overview. Evidence-Based Complement Alternat Med. 2005;2(4):465–73. Kwatra D et al. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evidence-Based Complementary and Alternative Medicine, 2013. 2013. Kwatra D et al. Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci. 2013;102(12):4444–54. Nkambo W, Anyama NG, Onegi B. In vivo hypoglycemic effect of methanolic fruit extract of Momordica charantia L. Afr Health Sci. 2013;13(4):933–9. Vyas A et al. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des. 2013;19(11):2047. Zhang D-W. Curcumin and diabetes: A systematic review. evidence-based complementary and alternative medicine, 2013. 2013. Panaskar SN et al. Aegle marmelos Correa leaf extract prevents secondary complications in streptozotocin‐induced diabetic rats and demonstration of limonene as a potent antiglycating agent. J Pharm Pharmacol. 2013;65(6):884–94. Subramaniam D et al. Activation of apoptosis by 1-hydroxy-5, 7-dimethoxy-2-naphthalene-carboxaldehyde, a novel compound from Aegle marmelos. Cancer Res. 2008;68(20):8573–81. Heiser CB. The gourd book. 1993: University of Oklahoma Press. Tindall HD. Vegetables in the tropics. Macmillan Press Ltd, 1983. Reyes M, Gildemacher B, Jansen G. Momordica L. Wageningon. Netherland: Pudoc Scientific Publishers; 1994. Marr KL, Mei XY, Bhattarai NK. Allozyme, morphological and nutritional analysis bearing on the domestication of Momordica charantia L. (Cucurbitaceae). Econ Bot. 2004;58(3):435–55. Grover J, Yadav S. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol. 2004;93(1):123–32. Wei L et al. Increase in the free radical scavenging capability of bitter gourd by a heat-drying process. Food Funct. 2013;4(12):1850–5. Zhu Y et al. Effect of superfine grinding on antidiabetic activity of bitter melon powder. Int J Mol Sci. 2012;13(11):14203–18. Chao C-Y et al. Anti-inflammatory effect of Momordica Charantia in sepsis mice. Molecules. 2014;19(8):12777–88. Costa JGM et al. Antibacterial activity of Momordica charantia (Curcubitaceae) extracts and fractions. J Basic Clin Pharma. 2010;2(1):45. Santos KK et al. Trypanocide, cytotoxic, and antifungal activities of Momordica charantia. Pharm Biol. 2012;50(2):162–6. Pongthanapisith V et al. Antiviral protein of Momordica charantia L. inhibits different subtypes of Influenza A. Evid Based Complement Alternat Med. 2013;2013:729081. Fang FE, Ng TB. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Molec Med. 2011;11(5):417–36. Lal J et al. In vitro anthelmintic action of some indigenous medicinal plants on Ascardia galli worms. Indian J Physiol Pharmacol. 1975;20(2):64–8. Frame AD et al. Plants from Puerto Rico with anti-Mycobacterium tuberculosis properties. P R Health Sci J. 1998;17(3):243–52. Ojewole J, Adewole SO, Olayiwola G. Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J South Africa: Off J Southern Africa Cardiac Soc South African Soc Cardiac Practitioners. 2005;17(5):227–32. Shih C-C, Lin C-H, Lin W-L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract. 2008;81(2):134–43. Deng Y-Y et al. Immunomodulatory activity and partial characterisation of polysaccharides from Momordica charantia. Molecules. 2014;19(9):13432–47. Manik S, Gauttam V, Kalia A. Anti-diabetic and antihyperlipidemic effect of allopolyherbal formulation in OGTT and STZ-induced diabetic rat model. 2013. Lu KH et al. Wild bitter gourd protects against alcoholic fatty liver in mice by attenuating oxidative stress and inflammatory responses. Food Funct. 2014;5(5):1027–37. Malik ZA, Singh M, Sharma P. Neuroprotective effect of Momordica charantia in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. J Ethnopharmacol. 2011;133(2):729–34. Haque ME, Alam MB, Hossain MS. The efficacy of cucurbitane type triterpenoids, glycosides and phenolic compounds isolated from Momordica charantia: a review. IJPSR. 2011;2(5):1135–46. Pitrat M, Chauvet M, Foury C. Diversity, history and production of cultivated cucurbits. in I International Symposium on Cucurbits 492, 1997. Decker-Walters DS. Cucurbits, sanskrit, and the Indo-Aryas 1. Econ Bot. 1999;53(1):98–112. Behera T et al. Morphological and molecular analyses define the genetic diversity of Asian bitter gourd (‘Momordica charantia’L.). 2012. Satyavati G, Raina M, Sharma M. Medicinal plants of India. vol. 1. New Delhi: Indian council of medical research; 1976. Yeşilada E, Gürbüz II, Sh H. Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity. J Ethnopharmacol. 1999;66(3):289–93. Chakravarty H. Cucurbits of India and their role in the development of vegetable crops. Biology and utilization of the cucurbitaceae. Ithaca: Comstock, Cornell University Press; 1990. Behera T et al. Minor cucurbits. genetics, genomics and breeding of cucurbits, 2011: p. 17. Behera TK et al. 2 bitter gourd: botany, horticulture, breeding. Hortic Rev. 2010;37:101. Thenmozhi AJ, Subramanian P. Antioxidant potential of Momordica charantia in ammonium chloride-induced hyperammonemic rats. Evidence-Based Complement Alternat Med, 2011. 2011. Lin K-W, Yang S-C, Lin C-N. Antioxidant constituents from the stems and fruits of Momordica charantia. Food Chem. 2011;127(2):609–14. Santos AK et al. Antioxidant activity of five Brazilian plants used as traditional medicines and food in Brazil. Pharmacogn Mag. 2010;6(24):335. Kumar R et al. In vitro evaluation of antioxidants of fruit extract of Momordica charantia L. on fibroblasts and keratinocytes. J Agric Food Chem. 2010;58(3):1518–22. Dhar P et al. Antioxidative effect of conjugated linolenic acid in diabetic and non-diabetic blood: an in vitro study. J Oleo Sci. 2007;56(1):19–24. Sulaiman SF, Ooi KL. Antioxidant and α-glucosidase inhibitory activities of cucurbit fruit vegetables and identification of active and major constituents from phenolic-rich extracts of Lagenaria siceraria and Sechium edule. J Agric Food Chem. 2013;61(42):10080–90. Ching R et al. Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring. J Nutr. 2011;141:1664–72. Tripathi UN, Chandra D. Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Momordica charantia pulp and Trigonella foenum graecum seed in alloxan-induced diabetic rats. 2010. Tripathi UN, Chandra D. The plant extracts of Momordica charantia and Trigonella foenum graecum have antioxidant and anti-hyperglycemic properties for cardiac tissue during diabetes mellitus. Oxidative Med Cell Longev. 2009;2(5):290–6. Chaturvedi P, George S. Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food. 2010;13(3):520–7. Teoh S, Latiff AA, Das S. Histological changes in the kidneys of experimental diabetic rats fed with Momordica charantia (bitter gourd) extract. Rom J Morphol Embryol. 2010;51(1):91–5. Teoh S, Latiff A, Das S. A histological study of the structural changes in the liver of streptozotocin-induced diabetic rats treated with or without Momordica charantia (bitter gourd). La Clinica Terapeutica. 2008;160(4):283–6. Xiang L et al. The reparative effects of Momordica Charantia Linn. extract on HIT-T15 pancreatic beta-cells. Asia Pac J Clin Nutr. 2007;16(1):249–52. Sathishsekar D, Subramanian S. Antioxidant properties of Momordica Charantia (bitter gourd) seeds on Streptozotocin induced diabetic rats. Asia Pac J Clin Nutr. 2005;14(2):153–8. Kavitha CN, Babu SM, Rao MB. Influence of Momordica charantia on oxidative stress-induced perturbations in brain monoamines and plasma corticosterone in albino rats. Indian J Pharmacol. 2011;43(4):424. Nerurkar PV et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011;8(64):2094–8. Chaturvedi P. Bitter melon protects against lipid peroxidation caused by immobilization stress in albino rats. Int J Vitam Nutr Res. 2009;79(1):48–56. Padmashree A et al. Studies on the antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models. J Sci Food Agric. 2011;91(4):776–82. De S, Ganguly C, Das S. Natural dietary agents can protect against DMBA genotoxicity in lymphocytes as revealed by single cell gel electrophoresis assay. Teratog Carcinog Mutagen. 2003;23(S1):71–8. Bao B et al. Momordica charantia (Bitter Melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues. PLoS One. 2013;8(12):e84075. Xu J et al. Bitter gourd inhibits the development of obesity-associated fatty liver in C57BL/6 mice fed a high-fat diet. J Nutrit. 2014;144(4):475–83. Hsieh C-H et al. Altered white adipose tissue protein profile in C57BL/6J mice displaying delipidative, inflammatory, and browning characteristics after bitter melon seed oil treatment. PLoS One. 2013;8(9):e72917. Cheng H-L et al. EMCD, a hypoglycemic triterpene isolated from Momordica charantia wild variant, attenuates TNF-α-induced inflammation in FL83B cells in an AMP-activated protein kinase-independent manner. Eur J Pharmacol. 2012;689(1):241–8. Jain V et al. Antinociceptive and antiallodynic effects of Momordica charantia L. in tibial and sural nerve transection-induced neuropathic pain in rats. Nutr Neurosci. 2014;17(2):88–96. Hsu C et al. Wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) extract and its bioactive components suppress Propionibacterium acnes-induced inflammation. Food Chem. 2012;135(3):976–84. Lii CK et al. Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol. 2009;122(2):227–33. Kobori M et al. Bitter gourd suppresses lipopolysaccharide-induced inflammatory responses. J Agric Food Chem. 2008;56(11):4004–11. Weng J et al. Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in Part, through peroxisome proliferator-activated receptor gamma activation. Evid Based Complement Alternat Med. 2013. Fang EF et al. RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis. 2012;17(4):377–87. Ray RB et al. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010;70(5):1925–31. Nagasawa H, Watanabe K, Inatomi H. Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med. 2002;30(02n03):195–205. Grossmann ME et al. Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prevent Res. 2009;2(10):879–86. Lee-Huang S et al. Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res. 1999;20(2A):653–9. Li C-J et al. Momordica charantia extract induces apoptosis in human cancer cells through caspase-and mitochondria-dependent pathways. Evidence-Based Complement Alternat Med. 2012;2012. Li S, Tse IM, Li ET. Maternal green tea extract supplementation to rats fed a high-fat diet ameliorates insulin resistance in adult male offspring. J Nutr Biochem. 2012;23(12):1655–60. Kupradinun P et al. Anticlastogenic and anticarcinogenic potential of Thai bitter: gourd fruits. Asian Pacific J Cancer Prevent. 2011;12(5):1299–305. Fan J-M et al. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol Biotechnol. 2008;39(1):79–86. Yasui Y et al. Bitter gourd seed fatty acid rich in 9c11t13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARγ in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fat Acids. 2005;73(2):113–9. Konishi T et al. A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound. Biofactors. 2004;22(1):71–4. Konishi T et al. Inhibitory effect of a bitter melon extract on the P‐glycoprotein activity in intestinal Caco‐2 cells. Br J Pharmacol. 2004;143(3):379–87. Deep G et al. Cancer preventive potential of Momordica charantia L. against benzo (a) pyrene induced forestomach tumourigenesis in murine model system. Indian J Exp Biol. 2004;42(3):319–22. Kohno H et al. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane‐induced rat colon carcinogenesis through elevation of colonic PPARγ expression and alteration of lipid composition. Int J Cancer. 2004;110(6):896–901. Kohno H et al. Dietary conjugated linolenic acid inhibits azoxymethane‐induced colonic aberrant crypt foci in rats. Cancer Sci. 2002;93(2):133–42. Kaur M et al. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis, 2013;bgt081. Fang EF et al. In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int J Biochem Cell Biol. 2012;44(8):1351–1360. Fang EF et al. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett. 2012;324(1):66–74. Ru P et al. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prevent Res. 2011;4(12):2122–30. Pitchakarn P et al. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett. 2011;306(2):142–50. Pitchakarn P et al. Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci. 2010;101(10):2234–40. Xiong SD et al. Ribosome‐inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase‐1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer. 2009;125(4):774–82. Agrawal R, Beohar T. Chemopreventive and anticarcinogenic effects of Momordica charantia extract. Asian Pacific J Cancer Prevent. 2010;11(2):371–5. Ganguly C, De S, Das S. Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. Eur J Cancer Prev. 2000;9(4):283–8. Singh A, Singh SP, Bamezai R. Momordica charantia (Bitter Gourd) peel, pulp, seed and whole fruit extract inhibits mouse skin papillomagenesis. Toxicol Lett. 1998;94(1):37–46. Limtrakul P et al. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. 2012. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol. 2004;54(6):525–30. Kai H et al. Inhibition of proliferation by agricultural plant extracts in seven human adult T-cell leukaemia (ATL)-related cell lines. J Nat Med. 2011;65(3–4):651–5. Kobori M et al. Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. J Agric Food Chem. 2008;56(22):10515–20. Takemoto D et al. Guanylate cyclase activity in human leukemic and normal lymphocytes. enzyme inhibition and cytotoxicity of plant extracts. Enzyme. 1981;27(3):179–88. Porro G et al. In vitro and in vivo properties of an anti-CD5—momordin immunotoxin on normal and neoplastic T lymphocytes. Cancer Immunol Immunother. 1993;36(5):346–50. Brennan VC, Wang C-M, Yang W-H. Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling. J Med Food. 2012;15(4):325–34. Claflin AJ et al. Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proc Natl Acad Sci. 1978;75(2):989–93. Hsu H-Y et al. Antimigratory effects of the methanol extract from Momordica charantia on human lung adenocarcinoma CL1 cells. Evidence-Based Complement Alternat Med. 2012;2012. Pan WL et al. Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia. Biochem Pharmacol. 2014;89(3):329–39. Rajamoorthi A et al. Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-met signaling. PLoS One. 2013;8(10):e78006.